Details
Stereochemistry | RACEMIC |
Molecular Formula | C17H9Cl3N4O2 |
Molecular Weight | 407.638 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC=C(C=C1)C(C#N)C2=C(Cl)C=C(C=C2Cl)N3N=CC(=O)NC3=O
InChI
InChIKey=ZSZFUDFOPOMEET-UHFFFAOYSA-N
InChI=1S/C17H9Cl3N4O2/c18-10-3-1-9(2-4-10)12(7-21)16-13(19)5-11(6-14(16)20)24-17(26)23-15(25)8-22-24/h1-6,8,12H,(H,23,25,26)
Molecular Formula | C17H9Cl3N4O2 |
Molecular Weight | 407.638 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=875c461a-e0db-4478-9006-7bd1d006ed3a
Curator's Comment: description was created based on several sources, including, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=875c461a-e0db-4478-9006-7bd1d006ed3a
Diclazuril is a main component of veterinary drugs used for the treatment of coccidiosis (chickens, turkeys, rabbits, etc) and equine protozoal myeloencephalitis (horses). When used for the treatment of coccidiosis, it acts by causing the degeneration of schizonts and gamonts. While in the animals affected by protozoal myeloencephalitis the drug is believed to inhibit merozoite production. In vivo experiments on horses have shown that the drug may cross the blood brain barrier.
CNS Activity
Sources: http://thomastobin.com/archive/240%20-%20Detection,%20Quantification%20and%20pharmacokinetics%20of%20Dic.pdf
Curator's Comment: The drug was shown to cross the BBB in horses.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Differentiation during parasite development |
|||
Target ID: Merozoite production |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | CLINACOX Approved UseFor the prevention of coccidiosis in animals. Launch Date9.2456642E11 |
|||
Curative | PROTAZIL Approved UseFor the treatment of equine protozoal myeloencephalitis (EPM) caused by Sarcocystis neurona. Launch Date1.17504003E12 |
PubMed
Title | Date | PubMed |
---|---|---|
In vitro quantitative analysis of (3)H-uracil incorporation by Sarcocytis neurona to determine efficacy of anti-protozoal agents. | 2001 Feb 26 |
|
Resistance to anticoccidial drugs of Dutch avian Eimeria spp. field isolates originating from 1996, 1999 and 2001. | 2003 Aug |
|
Efficient and sensitive detection of residues of nine coccidiostats in egg and muscle by liquid chromatography-electrospray tandem mass spectrometry. | 2004 Dec 25 |
|
[Comparison of the proteome of the sporutated oocysts of Eimeria tenella diclazuril sensitive strain with diclazuril resistant strain]. | 2005 May |
|
Deposition and depletion of five anticoccidials in eggs. | 2005 Sep 7 |
|
The efficacy and economic benefits of Supercox, a live anticoccidial vaccine in a commercial trial in broiler chickens in China. | 2006 Nov 30 |
|
Higher incidence of Eimeria spp. field isolates sensitive for diclazuril and monensin associated with the use of live coccidiosis vaccination with paracox-5 in broiler farms. | 2006 Sep |
|
Increased level of Eimeria sensitivity to diclazuril after using a live coccidial vaccine. | 2006 Sep |
|
New therapeutic approaches for equine protozoal myeloencephalitis: pharmacokinetics of diclazuril sodium salts in horses. | 2006 Spring |
|
Efficacy of some anticoccidial drugs for treating coccidial enteritis of the common carp caused by Goussia carpelli (Apicomplexa: Eimeriidae). | 2007 Mar |
|
Use of antigen mimics to produce specific antibodies to anti-coccidial drugs. | 2007 May 31 |
|
The effect of a metaphylactic treatment with diclazuril (Vecoxan) on the oocyst excretion and growth performance of calves exposed to a natural Eimeria infection. | 2007 Nov 10 |
|
Comparison of three adjuvants used to produce polyclonal antibodies to veterinary drugs. | 2008 Mar 15 |
|
Study of the comparative efficacy of toltrazuril and diclazuril against ovine coccidiosis in housed lambs. | 2009 Aug |
|
[Comparison of pretreatment methods for the simultaneous determination of diclazuril and toltrazuril residues in chicken tissues]. | 2009 May |
|
Fast liquid chromatography/multiple-stage mass spectrometry of coccidiostats. | 2009 May |
|
Multi-residue confirmatory method for the determination of twelve coccidiostats in chicken liver using liquid chromatography tandem mass spectrometry. | 2009 Nov 13 |
|
Validation of a multi-residue liquid chromatography-tandem mass spectrometry confirmatory method for 10 anticoccidials in eggs according to Commission Decision 2002/657/EC. | 2009 Nov 13 |
|
Sensitivity of isolates of Eimeria from turkey flocks to the anticoccidial drugs amprolium, clopidol, diclazuril, and monensin. | 2009 Sep |
|
Multi-residue method for detecting coccidiostats at carry-over level in feed by HPLC-MS/MS. | 2010 Jun |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: http://www.accessdata.fda.gov/scripts/animaldrugsatfda/details.cfm?dn=141-268
Coccidiosis: Mix 200 gram of Clinacox 0.5% premix per ton of complete feed. Equine protozoal myeloencephalitis: 1 milligram per kilogram of body weight in the daily grain ration for 28 days
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 02:10:08 UTC 2023
by
admin
on
Thu Jul 06 02:10:08 UTC 2023
|
Record UNII |
K110K1B1VE
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 520.606
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
||
|
CFR |
21 CFR 558.198
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
||
|
WHO-VATC |
QP51AJ03
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
||
|
NCI_THESAURUS |
C277
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
||
|
CFR |
21 CFR 556.185
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
K110K1B1VE
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
PRIMARY | |||
|
K110K1B1VE
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
PRIMARY | |||
|
1368201
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
PRIMARY | RxNorm | ||
|
1188560
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
PRIMARY | |||
|
456389
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
PRIMARY | |||
|
M4360
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL284733
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
PRIMARY | |||
|
5971
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
PRIMARY | |||
|
Y-61
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
PRIMARY | |||
|
100000082936
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
PRIMARY | |||
|
101831-37-2
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
PRIMARY | |||
|
C76418
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
PRIMARY | |||
|
DB11398
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
PRIMARY | |||
|
DICLAZURIL
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
PRIMARY | |||
|
C057884
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
PRIMARY | |||
|
SUB07091MIG
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
PRIMARY | |||
|
759642
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
PRIMARY | |||
|
DTXSID4046787
Created by
admin on Thu Jul 06 02:10:08 UTC 2023 , Edited by admin on Thu Jul 06 02:10:08 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
SALT/SOLVATE -> PARENT | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
Specific limit is not given. Any other impurity-0.25% peak area.
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
Specific limit is not given. Any other impurity - 0.25% peak area.
EP
|
||
|
IMPURITY -> PARENT |
Specific limit is not given. Any other impurity - 0.25% peak area.
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.9
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.4; Specific limit not given. Any other impurity-0.25% peak area.
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
Specific limit is not given. Any other impurity - 0.25% peak area.
EP
|
||
|
IMPURITY -> PARENT |
Specific limit is not given. Any other impurity - 0.25% peak area.
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
Specific limit is not given. Any other impurity - 0.25% peak area.
EP
|
||
|
IMPURITY -> PARENT |
Specific limit is not given. Any other impurity - 0.25% peak area.
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |